Results 1 to 10 of about 97,287 (310)

Prevalence, risk factors, and treatment outcomes of isoniazid- and rifampicin-mono-resistant pulmonary tuberculosis in Lima, Peru [PDF]

, 2016
Background : Isoniazid and rifampicin are the two most efficacious first-line agents for tuberculosis (TB) treatment. We assessed the prevalence of isoniazid and rifampicin mono-resistance, associated risk factors, and the association of mono-resistance ...
Gotuzzo, Eduardo, Huaman, Moises A, Otero Vegas, Larissa, Seas, Carlos, Sterling, Timothy R, Van Der Stuyft, Patrick, Villegas, Leonela   +6 more
core   +42 more sources

Determination of Isoniazid by Fe(II)-2,2’-Bipyridine Spectrophotometry [PDF]

E3S Web of Conferences, 2021
In acidic media, Fe(Ш) could be reduced to Fe(Ⅱ) by isoniazid, Fe(Ⅱ) reacts with 2,2'-bipyridine to form an orange complex with a maximum absorption wavelength of 522 nm. According to this principle, the content of isoniazid can be measured indirectly by
Tu Changqing, Wen Xinrong
doaj   +1 more source

Pyrazinamide resistance in rifampicin discordant tuberculosis.

PLoS ONE, 2022
IntroductionMycobacterium tuberculosis strains with phenotypically susceptible rpoB mutations (rifampicin discordant) have emerged following implementation of rapid molecular drug resistance testing for tuberculosis. Whilst rifampicin resistance is known
Nomonde Ritta Mvelase, Ravesh Singh, Khine Swe Swe-Han, Koleka Patience Mlisana   +3 more
doaj   +2 more sources

The Effects of Isoniazid on the Acquisition and Expression of Morphine-Induced Conditioned Place Preference in Mice [PDF]

Journal of Kerman University of Medical Sciences, 2020
Background: GABAergic drugs can modulate the rewarding properties of morphine. The objective of this study was to evaluate the effects of isoniazid, as a GABAergic agent, on the rewarding effects of morphine.
Amir Barzegari, Kamran Shahabi
doaj   +1 more source

Prevalence, risk factors and treatment outcomes of isoniazid resistant TB in Bulawayo city, Zimbabwe: A cohort study

Journal of Infection in Developing Countries, 2020
Introduction: The isoniazid-resistant TB poses a threat to TB control efforts. Zimbabwe, one of the high TB burden countries, has not explored the burden of isoniazid resistant TB.
Barbara Manyame-Murwira, Kudakwashe Collins Takarinda, Pruthu Thekkur, Bright Payera, Herbert Mutunzi, Raiva Simbi, Nicholas Siziba, Edwin Sibanda, Catherine Banana, Norbert Muleya, Evidence Makombe, Paula Littia Jongwe, Regina Bhebhe, Douglas Mangwanya, Janet Dzangare, Fungai Hamilton Mudzengerere, Collins Timire, Enock Wekiya, Charles Sandy   +18 more
doaj   +1 more source

Negligible risk of inducing resistance in Mycobacterium tuberculosis with single-dose rifampicin as post-exposure prophylaxis for leprosy [PDF]

, 2016
Post-exposure prophylaxis (PEP) for leprosy is administered as one single dose of rifampicin (SDR) to the contacts of newly diagnosed leprosy patients. SDR reduces the risk of developing leprosy among contacts by around 60 % in the first 2-3 years after ...
Anthony, Richard, Bratschi, Martin W., Cambau, Emmanuelle, Cavaliero, Arielle, Kasang, Christa, Mieras, Liesbeth, Perera, Geethal, Reichman, Lee, Richardus, Jan Hendrik, Saunderson, Paul, Steinmann, Peter, van Brakel, Wim, van den Broek, Jacques, Yew, Wing Wai   +13 more
core   +10 more sources

Barriers in the implementation of isoniazid preventive therapy for people living with HIV in Northern Ethiopia: a mixed quantitative and qualitative study

BMC Public Health, 2016
Background Isoniazid preventive therapy is a key public health intervention for the prevention of tuberculosis disease among people living with HIV. Despite the confirmed efficacy of isoniazid preventive therapy and global recommendations existing for ...
Gebrehiwot Teklay, Tsigemariam Teklu, Befikadu Legesse, Kiros Tedla, Eveline Klinkenberg   +4 more
doaj   +1 more source

Chronic dialysis, NAT2 polymorphisms, and the risk of isoniazid-induced encephalopathy – case report and literature review

BMC Nephrology, 2017
Background Isoniazid is the most widely used anti-tuberculosis agent, yet it may lead to life-threatening complications. Case presentation Here we report the case of a chronic hemodialysis patient who developed severe encephalopathy after the start of ...
Stefan Matei Constantinescu, Benoit Buysschaert, Vincent Haufroid, Franck Broly, Michel Jadoul, Johann Morelle   +5 more
doaj   +1 more source

The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis [PDF]

, 2003
Patients in whom acid-fast bacilli smear-positive pulmonary tuberculosis was newly diagnosed were randomized to receive 400 mg moxifloxacin, 300 mg isonaizid, or 600 mg rifampin daily for 5 days. Sixteen-hour overnight sputa collections were made for the
Bongard, E, Gillespie, SH, Gosling, RD, Kanduma, EG, Morris, RW, Nyindo, M, Sam, NE, Uiso, LO   +7 more
core   +1 more source

PLA Microparticles for Pulmonary Delivery of AntiTB drugs: Biodistribution study [PDF]

, 2008
A dry powder inhalable (DPI) microparticles comprising anti-tuberculosis drugs incorporated in biodegradable polymers was developed for the treatment of pulmonary tuberculosis (P. Muttil _et al_. 2007).
Amit Misra, Awadh Bihari Yadav, Jatinder Kaur, Kauslender Kumar, Rahul Kumar Verma   +4 more
core   +2 more sources